Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Sees Significant Decrease in Short Interest

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 27,133 shares, a decline of 66.6% from the December 31st total of 81,204 shares. Based on an average daily trading volume, of 30,983 shares, the short-interest ratio is presently 0.9 days. Approximately 0.2% of the company’s stock are sold short. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 30,983 shares, the short-interest ratio is presently 0.9 days.

Hong Kong Pharma Digital Technology Trading Down 5.2%

HKPD stock traded down $0.04 during midday trading on Thursday, reaching $0.80. 49,220 shares of the company were exchanged, compared to its average volume of 26,957. Hong Kong Pharma Digital Technology has a one year low of $0.68 and a one year high of $2.76. The business has a 50-day moving average price of $0.82 and a two-hundred day moving average price of $1.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Hong Kong Pharma Digital Technology in a report on Friday, January 9th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.